Idasanutlin exposure was universally associated with potent, on-target, cytotoxic activity at subclinical concentrations in the absence of TP53 inactivating mutations, promoting p53 activation as a promising therapeutic strategy in ALL. Here, TP53 is linked to acute lymphoblastic leukemia.